Pharmagreen Biotech (Pharmagreen Biotech) Change In Working Capital : $0.24 Mil (TTM As of Jun. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Pharmagreen Biotech Change In Working Capital?

Pharmagreen Biotech's change in working capital for the quarter that ended in Jun. 2023 was $0.10 Mil.

Pharmagreen Biotech's change in working capital for the fiscal year that ended in Sep. 2022 was $0.24 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Pharmagreen Biotech Change In Working Capital Historical Data

The historical data trend for Pharmagreen Biotech's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmagreen Biotech Change In Working Capital Chart

Pharmagreen Biotech Annual Data

Trend

Apr08

Apr09

Sep18

Sep19

Sep20

Sep21

Sep22

Change In Working Capital

Get a 7-Day Free Trial

-0.04

0.16

-0.13

-0.09

0.24

Pharmagreen Biotech Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Change In Working Capital	Get a 7-Day Free Trial															0.24	-0.05	0.09	0.09	0.10

Pharmagreen Biotech Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.24 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Pharmagreen Biotech Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Pharmagreen Biotech's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmagreen Biotech (Pharmagreen Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmagreen Biotech Inc (OTCPK:PHBI) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

112 North Curry Street, Carson, NV, USA, 89703

Website

https://www.pharmagreen.ca

Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.